Home › Long COVID › Colorado › Aurora
Long COVID clinical trials in Aurora, CO
3 studies for Long COVID are looking for participants at sites in and around Aurora (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
A Study to Learn About the Study Medicine Ibuzatrelvir in Adults With COVID-19 Who Are Severely Immunocompromised
RecruitingPhase 3
- UCHealth Anschutz Inpatient Pavilion - Anschutz Medical Campus, Aurora
- University of Colorado Anschutz Medical Campus, Aurora
- University of Colorado Clinical and Translational Research Center, Aurora
- and 1 more
Randomized Double-Blind Placebo-Controlled Trial EValuating Baricitinib on PERSistent NEurologic and Cardiopulmonary Symptoms of Long COVID
RecruitingPhase 3
- University of Colorado I Anschutz Medical Campus, Aurora
Physiology of Long COVID-19 and the Impact of Cardiopulmonary Rehabilitation on Quality-of-Life and Functional Capacity
RecruitingHealthy volunteers welcome
- University of Colorado Hospital, Aurora
About Long COVID
Anyone who has had COVID-19 can have long-lasting symptoms, know as long COVID. Learn about the symptoms and how to manage them, diagnosis, and prevention.
More about Long COVID on MedlinePlus
Long COVID trials in other cities
- New York City, NY17 studies
- Houston, TX14 studies
- Chicago, IL12 studies
- Washington, DC12 studies
- Boston, MA11 studies
- Baltimore, MD11 studies
- Hialeah, FL8 studies
- Durham, NC8 studies
- San Francisco, CA8 studies
- Atlanta, GA7 studies
- San Diego, CA7 studies
- Miami, FL7 studies
Other studies in Aurora
- Cancer (all types)34 studies
- Colorectal Cancer33 studies
- Non-Small Cell Lung Cancer31 studies
- Breast Cancer30 studies
- Type 1 Diabetes26 studies
- Metastatic Cancer24 studies
- Ovarian Cancer23 studies
- Obesity20 studies
- Lung Cancer19 studies
- Melanoma18 studies
- Heart Failure17 studies
- Prostate Cancer17 studies
From ClinicalTrials.gov, data retrieved Nov 15, 2026. Each study sets its own eligibility; the study team decides who can join.